Cholangiocarcinoma Foundation logo
DONATE

2026 Annual Conference Poster Presentations

1 – Developing a Blood-Based Test for Diagnosis, Prognosis, and Monitoring of Cholangiocarcinoma
2 – Development of a Polygenic Risk Score to Predict Recurrence and Survival in Patients With Resected Cholangiocarcinoma
3 – BAP1 Loss Confers Ferroptosis Resistance to CCA via TLCD1-Mediated Mitochondrial Membrane Phospholipid Remodeling
4 – Therapy-Induced Cancer Cell Senescence Promotes Tumor Immunosuppression in Cholangiocarcinoma
5 – Targeting Pin1 in Cholangiocarcinoma Tumor and Stromal Cells Using siRNA Therapeutics
6 – Characterization of Tropomyosin Receptor Kinase Signaling in Intrahepatic Cholangiocarcinoma
7 – Development of Novel Blood-Based Glycopeptide Biomarkers for the Diagnosis of Cholangiocarcinoma
8 – Mapping the Tumor and Immune Microenvironment in Anatomically Diverse Subtypes of Cholangiocarcinoma
9 – Therapeutic Targeting of the KRAS in BTC
10 – Ellis, Haley_MAPK Pathway Mutations Emerge in mIDH1i-Resistant CCA and Attenuate the IFN Response – Haley Ellis
11 – Development and Characterization of Novel Cholangiocarcinoma Cell Sublines Resistant to Cisplatin or 5-Fluorouracil
13 – Clinical Features and Transcriptomic Landscape of SWI:SNF-Mutated Biliary Tract Cancers
14 – TEAD Inhibition by IAG933 as a Novel Therapeutic Strategy for Cholangiocarcinoma
15 – Defining Transcriptional Phenotypes and Heterogeneity Across Biliary Tract Cancers and Matched PDX Models
16 – Functional Screening of ARID1A-Deficient Cholangiocarcinoma Using the MAPS Platform
17 – A Novel Immuno-Oncology Preclinical Pipeline to Study FGFR2 Fusion-Driven Cholangiocarcinoma
18 – Concurrent ARID1A:PBRM1 Loss Reorganizes Chromatin Accessibility Through SWI:SNF Complex Redistribution in Cholangiocarcinoma
19 – Aptamer-Targeted Delivery of siRNA Therapeutics for Cholangiocarcinoma
20 – Characterizing Genomic, Transcriptomic and Clinical Landscape in CCNE:CCND Amplified Biliary Tract Cancer
21 – IRAK4 Inhibitor Is a Potential Target for the Treatment of Biliary Tract Cancer
22 – A 6-Gene pSTAT3 Transcriptomic Score Identifies an Immunosuppressive, Chemotherapy-Resistant Phenotype and Predicts Poor Survival in Biliary Tract Cancer
23 – Functional and Mechanistic Role of lncRNA-A1 in Colangiocarcinoma
24 – Relevance of Chemokines in Mobilising γδ T Cells in the Biliary Tract Cancer Microenvironment
25 – Transcriptome Profiling Identifies TIGIT and PD-1 Co-Expression in the Immunosuppressive Environment in Cholangiocarcinoma
26 – Rapid Research Autopsy Unravels Clonal Drivers of Metastatic Progression in FGFR2-Driven Cholangiocarcinoma
28 – Biliary Tracts Cancer Consensus Molecular Subtypes Improve Outcome Stratification Over Anatomy
29 – Immunotherapy as a Neoadjuvant Treatment in Liver Transplant Recipients With Cholangiocarcinoma
30 – Association Between Postoperative GNRI and Chemotherapy Dose Intensity With Survival Outcomes in Biliary Tract Cancer
31 – Radiation Therapy and Durvalumab in Cholangiocarcinoma – Survival Outcomes
32 – Durvalumab or Pembrolizumab Plus GemCis in Advanced Cholangiocarcinoma – Meta-Analysis
33 – Four-Year Survival and Safety Analysis From TOPAZ-1
34 – First-Line Rilvegostomig Plus Chemotherapy in Advanced Biliary Tract Cancer – GEMINI-Hepatobiliary Substudy 2 Cohort A
35 – Combined Treatment of Durvalumab, Bevacizumab and Tremelimumab in Subjects With Biliary Tract Carcinoma (BTC)
36 – Single-Center Experience With Chemo-Immunotherapy Plus HAI Floxuridine in iCCA
37 – Efficacy and Safety of Lirafugratinib in FGFRi-Naïve Cholangiocarcinoma (CCA) Patients Harboring FGFR2 Fusions:Rearrangements
38 – Survival and Safety Data With Tinengotinib in FGFR-Refractory Cholangiocarcinoma
39 – Zenocutuzumab Efficacy and Safety in Advanced NRG1+ Cholangiocarcinoma – Analysis From the Phase 2 eNRGy Trial
40 – Continued Zenocutuzumab Beyond Progression in NRG1+ Cancers
41 – Ivosidenib Plus Durvalumab and GemCis in IDH1-Mutant Cholangiocarcinoma
42 – A Phase 1:2 Trial Investigating Ivosidenib Plus Nivolumab and Ipilimumab in Patients With Previously Treated mIDH1 CCA
43 – First-in-Human Study of BA3182 in Metastatic Adenocarcinoma
44 – AI-Assisted Clinical Trial Matching for Cholangiocarcinoma Patients
45 – AI Starter – Medical Image Analysis for Cholangiocarcinoma Projects
46 – Hope, Loneliness, and Cancer-Related Experiences Among Canadians Affected by Biliary Tract Cancers
47 – EUS-Guided Gallbladder Drainage After Endobiliary RFA
48 – Cholangiocarcinoma Incidence in 119,469,528 Adults in the US – 2017-2024
49 – ARIMA 2030 Projections and Epidemiology Across Asian Countries
50 – Unexpected Burden of Cholangiocarcinoma in a Prospective Population-Based Cohort in Gipuzkoa Province (Spain: 2010–2024)
51 – Association Between Diabetes and Gallbladder Cancer Risk Among Chilean Women with Gallstones: Findings from the Chile Biliary Longitudinal Study
53 – BiliSeq Improves Detection of Malignancy in Biliary Strictures
54 – Impact of a National Molecular Testing Program in BTC
55 – Factors Associated With Resectable and Unresectable BTC
56 – Y90 Glass Microsphere Treatment for iCCA – PROACTIF Results
57 – Real-World Outcomes of Durvalumab Plus GemCis in BTC
58 – Real-World Outcomes of Durvalumab Plus GemCis in Cholangiocarcinoma
59 – Real-World Outcomes of GemCis Plus Immunotherapy in BTC
60 – Treatment Patterns in Extrahepatic Cholangiocarcinoma With Autoimmune Conditions
61 – Treatment Patterns in Intrahepatic Cholangiocarcinoma With Autoimmune Comorbidities
62 – Treatment Outcomes of Patients With mIDH1 Cholangiocarcinoma in the United States
63 – Therapeutic Targeting of IDH1 Mutations in Intrahepatic Cholangiocarcinoma Arising in Ollier Disease
64 – Real-World Outcomes With Supportive Care vs Anticancer Therapy in BTC
65 – Global Patient Interviews on BTC Diagnosis and Treatment Journey
66 – Aflatoxin and Extrahepatic Bile Duct Cancer – A Planned Study
67 – Beacon-BTC – Phase 3 Study of Nanvuranlat in Advanced BTC
68 – HYPERION CCA – Chemoimmunotherapy With or Without Radiation in iCCA
69 – Pemigatinib With Atezolizumab and Bevacizumab in Advanced Cholangiocarcinoma
70 – ATTAINMENT – Phase lb Trial of MDX-124 in Advanced Solid Tumors
71 – A Phase I:II Study of CDX-1140, CAPOX and Pembrolizumab in Second-Line Biliary Tract Cancer
72 – Phase 1:2 Study of VS-7375 in KRAS G12D-Mutant Tumors